Conference Presentations

7th Southern African HIV Clinicians Society (SAHCS) conference 2025 – Presentations:

Wednesday, 20 August 2025

Session 1: Advances in paediatric HIV treatment – Mo Archary
Session 1: Progress on the TB Recovery Plan – Norbert Ndjeka
Session 2A: Innovative strategies for the control and prevention of STI’s – Katherine Gill
Session 2A: Syphilis and congenital syphilis and just triple elimination as a concept – Tendesayi Kufa-Chakezha
Session 2A: New set of STI guidelines – what has changed – Nigel Garrett
Session 2B: CHAPAS-4 trial – Victor Musiime
Session 2B: Suppression in under 5s – DTG vs PIs – Ahmad Haeri Mazanderani
Session 2C: Isoniazid preventative therapy should only be initiated at CD4 < 350 – Karen Cohen
Session 2C: Debate: Should tuberculosis preventive therapy (TPT) be given to women living with HIV during pregnancy? –Norbert Ndjeka
Session 2C: Debate: Should tuberculosis preventive therapy (TPT) be given to women living with HIV during pregnancy? – Jenny Nash
Session 3A: Update on the TB vaccines – Mark Hatherill
Session 3A: What’s new in the guidelines – Juli Switala
Session 3C: Integrating HIV and noncommunicable diseases care in South African primary
healthcare: policy considerations – Ntobeko Ntusi
Session 5A: Acceptability and uptake of Liraglutide for management of obesity in people living with HIV in rural KwaZulu-Natal – Ngundu Behuhuma
Session 5B: Long-acting injectable lenacapavir – Katherine Gill
Session 5B: PrEP and pregnancy, and other methods – Dvora Joseph-Davey
Session 5B: Cabotegravir long-acting – HPTN 084 open label extension updates – Sinead Delany-Moretlwe
Session 5C: IMPIRICAL trial – Victor Musiime
Session 6: Why are we seeing more DTG resistance in programmatic scenarios? – Catherine Orrell

Thursday, 21 August 2025

Session 7A: The role of cultural competence in improving HIV outcomes – Nthuseni Murudi-Manganye
Session 7B: What is a mentor? – Nomathemba Chandiwana and Keitumetse Lebelo
Session 8: ART adherence and retention – Catherine Orrell
Session 8: Systematic review and meta-analysis of the efficacy of intermittent antiretroviral therapy dosing: a crisis response to the sudden cuts in USAID and PEPFAR funding – Francois Venter
Session 9A: Reflex drug exposure assessment in clinical practice: Results of ITREMA-2 – Kim Steegen
Session 9B: Community-led monitoring of HIV and related services – Lotti Rutter
Session 9C: Mental health screening tools – Julia Turner
Session 9C: Using task sharing for screening for common mental health conditions within primary health care – Inge Petersen
Session 9C: Mental health integration into primary care – Melissa Wallace
Session 10A: Endemic mycoses – David Stead
Session 10B: Upcoming SAHCS guideline on ageing with HIV – Evan Shoul
Session 10B: The biology and epidemiology of ageing with HIV – Marshall Glesby
Session 10B: Menopause and women living with HIV – Rosie Mngqibisa
Session 10C: Care transition for pregnant adolescents – Nosisa Sipambo
Session 12A: Future options for prevention – Shaun Barnabas
Session 12A: Where are we in the elimination of VTP and what needs to happen to close the gaps – Ahmad Haeri Mazanderani
Session 12B: Existing and emerging vaccines and therapeutic strategies – Justin Shenje
Session 12B: Review of existing and new TB diagnostics – Norbert Ndjeka
Session 12B: Drug-resistant and drug-sensitive TB – Kogie Naidoo
Session 12C: Stigma – The elephant in the room – Julia Turner and Themba Nxumalo
Session 13A: The impact of community-based management through NIMART on health outcomes for patients with HIV – Musa Manganye
Session 13A: Importance of reporting and data, and the impact therein of the US funding cuts – Francois Venter
Session 13B: A moral philosopher’s approach to navigating the ethics of assisted dying – Heidi Matisonn
Session 13C: A refresher on drug interactions – Gary Maartens

Friday, 22 August 2025

Session 16: From HIV entry to eradication: the role of CCR5 in HIV cure research – Caroline Tiemessen
Session 16: Timing of HIV-1 reservoir establishment in women with chronic HIV infection – Melissa-Rose Abrahams
Session 17A: HIV and cardiometabolic disease – Ntobeko Ntusi
Session 17A: The REPRIEVE study: Should we routinely be using statins in African ARV programmes? – Jeremy Nel
Session 17A: Acute renal failure after starting ART: an approach – Lauren Richards
Session 17A: Sleep and HIV – Nomathemba Chandiwana
Session 17B: Update on the progress of implementation projects including introduction of the dapivirine ring and cabotegravir – Elzette Rousseau
Session 17B: Advancing the delivery of PrEP method choice for AGYW and key populations through diverse models and approaches – Nicolette Naidoo
Session 17B: Closing the Gap: How pharmacies can drive long-acting PrEP uptake – Tsitsi Nyamuzihwa
Session 18A: SAHCS guideline on the management of Non-Tuberculous Mycobacteria in people living with HIV – Halima Dawood
Session 18B: Evolution of resistance, use of next generation sequencing and considerations for management – Nazir Ismail
Session 18C: HIV treatment adherence overview – Silingene Ngcobo
Session 18C: Person centred care – Sharon Kruger
Session 18C: What we encounter in clinical practice – Natasha Davies
Session 18C: Improving treatment outcomes through use of participatory “adherence games” with newly initiated ART patients – Peter Labouchere
Session 19A: Partner HIV self-testing as a predictor and facilitator of PrEP adherence among pregnant and lactating women in Cape Town: A mixed-methods analysis – Kalisha Bheemraj
Session 19A: Association between timing of ART initiation or reinitiation and neuroimaging-confirmed stroke in PWH – Roland van Rensburg
Session 19A: Quality improvement entrenchment and collaborative partnerships following implementation of the 100 facilities initiative to improve the second 95 of the HIV cascade, Cape Town – Aurelie Nelson
Session 19A: Multi-dose PK/Safety of Dolutegravir dispersible tablets & oral films in neonates: Petite-DTG study – Adrie Bekker
Session 19A: Characterizing latent profiles of young long-acting injectable PrEP users in Cape Town – Elzette Rousseau
Session 19A: Impact of urine TFV testing on PrEP adherence in South African pregnant & postpartum women: an RCT – Dvora Joseph-Davey
Session 19B: Long-acting treatment options – Catherine Orrell
Session 20B: Challenges in translating the U=U from sexual transmission to breastfeeding transmission – Natasha Davies
Session 20C: From Chronic to Cured: Hepatitis C management in the era of direct acting antivirals – Andrew Scheibe
Session 20C: The indirect effects of CMV: Can treating CMV viraemia lower mortality in Advanced HIV? – Lauren Richards
Session 20C: Mpox: the latest – Jeremy Nel

Poster Abstracts:

4 Improving treatment outcomes through use of participatory “adherence games” with newly initiated ART patients – Peter Labouchere

10 The Burden of TB and Cryptococcosis amongst hospitalized adults in the Era of Widespread Antiretroviral Treatment (ART): Insights from Minimally Invasive Tissue Sampling (MITS) – Marguerite Hall

12 Determinants associated with Advanced HIV Disease among adults-initiated ART in Ethiopia – Sheillah Hlamalani Mboweni

14 Long-Term Mortality Trends and Non-Communicable Disease Burden Among HIV-Positive Members of medical schemes administered by Discovery Health (2012–2024) – Xolani Masombuka

16 TAF achieves adequate intracellular tenofovir diphosphate concentrations with rifampicin based TB therapy – Rephaim Mpofu

19 Reimagining HIV and TB Care through a Medicine of Breath and Fracture – Hichem Ben Azouz

25 Grave’s IRIS and pancytopaenia -Maryke de Villiers

29 Cross-Sectional Study of the Prevalence and Risk Factors of Resistant Hypertension among HIV-Positive Adults with Hypertension Attending Newlands Clinic, Zimbabwe (2025) – Wilson Marikopo

30 Metformin Improves Endothelial Function in a Subset of Women with HIV and Metabolic Syndrome: Results from a Pilot Study – Eric Decloedt

38 Exploring the experiences of nurses in providing HIV self-management discharge information – Mellissa Arison

39 Prevalence, predictors and geospatial patterns of HIV drug resistance in South Africa among the virally unsuppressed adults: Insights from the 2017 national HIV household survey – Mpho Seleka

40 Antiretroviral drug resistance testing among patients on second-line therapy in a tertiary hospital in Tshwane, South Africa: a retrospective study – Amanda Dlamini

41 Closing the Gaps in CrAg Testing: Lessons from an Implementation Assessment in Guinea – Jonathan Falconer

46 Missed opportunities for HIV testing among medical admissions in SA – ADVANCE GERMS – Juliet Rundogo

47 Hepatitis B seroprevalence amongst HIV infected adults in the Free State, South Africa – Devon Muir

49 Atypical Hepatitis B surface antigen escape mutations in an HIV infected patient in South Africa – Menzi Nkosi

53 Sepsis-associated Mortality Among Hospitalized Adults in the Era of Widespread Antiretroviral Therapy: Preliminary Insights from Minimally Invasive Tissue Sampling – Marguerite Hall

54 PATHWAY TO CARE AMONG INPATIENTS WITH SYMPTOMATIC CRYPTOCOCCAL MENINGITIS IN GQEBERHA, SOUTH AFRICA – Lia Frances Edkins

55 Epidemiology of neurosyphilis in a secondary hospital in Cape Town – Teagan Van Wyk

56 Aetiology and outcomes of meningitis in adults: a retrospective audit in the anti-retroviral era from a district-level hospital in Cape Town – Kyla Murphy

59 Strengthening Health systems through Audit and Programmatic data Evaluation – Paediatric Assessment of Ethekwini Dolutegravir Switches (SHAPE-PAEDS) -Yukteshwar Sookrajh

60 Psychosocial support and HIV-related stigma intervention needs of adolescents living with HIV in southern Ethiopia: Insights from adolescents, caregivers, and healthcare providers – Melkamu Merid Mengesha

62 Exploring new diagnostic options for HIV Early Infant Diagnosis – Cherise Naicker

69 Patient Satisfaction with the Central Chronic Medicines Dispensing and Distribution (CCMDD) Programme in South Africa: Implications for HIV Differentiated Service Delivery – Nishana Ramdas

70 Missed Opportunities in HIV care among patients with invasive non-typhoidal salmonellosis: Insights from GERMS-SA surveillance data, 2021–2023 – Tiisetso Lebaka

73 Post-TB lung disease in HIV patients in Kinshasa, Democratic Republic of Congo (DRC): case series of hospitalised patients requiring long-term oxygen therapy – Patrick Kisaka

74 Utilisation of diagnostic modalities for TB meningitis in a district hospital in Cape Town – Teagan Van Wyk

_______________________________________________________________________________________________________

PAST CONFERENCE PRESENTATIONS:

6th Southern African HIV Clinicians Society (SAHCS) conference 2023 – Presentations:

Wednesday, 8 November 2023

Session 1: Advances in adult HIV treatment from 2000 to current (Linda-Gail Bekker)

Session 1: Advances in paediatric HIV treatment from 2000 to current (Moherndran Archary)

Session 1: Progress on the TB recovery plan (post COVID-19) (Norbert Ndjeka)

Session 2A: Advanced HIV diseases (Tom Boyles)

Session 2A: Renal (Phetho Mangena)

Session 2A: Photosensitive rashes in HIV (Lehlohonolo Makhakhe)

Session 2B: Updated ARV drug dosing chart for children (James Nuttall)

Session 2B: Disclosure (Julia Turner)

Session 4A: ADVANCE study – Review of the primary results, sub-studies and potential plans in the future (Francois Venter)

Session 4A: TDF versus TAF toxicities (Rephaim Mpofu)

Session 4A: Weight gain on current ART (Phumla Sinxadi)

Session 4B: Adolescent girls and young women (AGYW) and pregnancy (Karl-Gunter Technau)

Session 4B: PrEP for pregnant and breastfeeding women (Otty Mhlongo)

Session 4B: Case vignettes: Common clinical and programmatic challenges in PBFW population (Natasha Davies)

Session 4C: Understanding the impact of COVID-19 and the national lockdown restrictions on sex worker uptake of health services in four sites in Gauteng: A retrospective record review (Khuthadzo Hlongwane)

Session 4C: Event driven PrEP: MSM (Jacqueline Pienaar)

Session 4C: ART outcomes among FSWs (Harry Hausler)

Session 5A: Overarching updated of HIVTF and HIVDR – update of recent literature (Gillian Hunt)

Session 5A: Current and new trials: HIVTF and HIVDR patterns (Lucas Hermans)

Session 5B: Diarrhoea (David Stead)

Session 5B: Nontuberculous mycobacteria – how to diagnose and treat, and drug resistance non-tuberculous mycobacteria (Tom Boyles)

Session 5C: Mental health-neuropsychiatry (John Joska)

Session 5C: Integration of HIV and NCD care (Samanta Lalla-Edward)

Session 6: PLWH and how they respond to COVID mRNA vaccines (Asa Tapley)

Session 6: TB prevention – what’s worked and what hasn’t worked in South Africa. Rifapentine regimen for prevention also the TB vaccines in the pipeline. (Norbert Ndjeka)

Thursday, 9 November 2023

Session 8: Molecular epidemiology of HIV in South Africa and its role in HIV prevention (Gillian Hunt)

Session 8: HIV prevention in pregnancy and postpartum period: Roles of PrEP (oral & new modalities) (Dvora Joseph-Davey)

Session 9A: Southern African HIV Clinicians Society guidelines for antiretroviral therapy in adults: 2023 update (Jeremy Nel)

Session 9A: Southern African HIV Clinicians Society 2022 guideline for the management of sexually transmitted infections (Remco Peters)

Session 9A: SAHCS PEP guidelines (Katherine Gill)

Session 9B: Old and New Tools for Diagnosing TB in 2023 (Lyle Murray)

Session 9B: Programme updates with respect to TB treatment (Ndiviwe Mphothulo)

Session 9B: TB meningitis and TB bacterium (Linda Boloko)

Session 9D: Key populations guidelines: WHO (Melanie Collins)

Session 9D: TG and affirming care / hormone therapy etc. training module (Elma De Vries)

Session 9D: Chem Sex: Engage men’s health – programme data and interventions (Dawie Nel)

Session 9D: Mental health and PWUD in the context HIV (Andrew Scheibe)

Session 11A: Roll out of the new ultra-short DR-TB regimen and update on the programme implementation (Norbert Ndjeka)

Session 11A: A Brave New world: TB research to implementation (Francesca Conradie)

Session 11B: Ethics in the time of social media (Theresa Rossouw)

Session 11B: Disclosure – to D or not to D (Graham Howarth)

Session 11C: Mastering the digital toolbox: Essential resources for nurses in HIV care (Julia Turner, Erin von der Heyden and Christi Jackson)

Session 12A: Task shifting being effective and safe in our context (Linda-Gail Bekker)

Session 12A: CAB-LA (Carey Pike)

Session 12A: What’s coming next in terms of PrEP (Thato Chidarikire)

Session 12B: The ITREMA three step strategy for therapy monitoring (Annemarie Wensing)

Session 12B: Drug exposure testing using point of care testing (CJ Umunnakwe)

Session 12B: Clinical experience with drug exposure testing: Case series (Jeremy Nel)

Session 12B: Drug exposure testing using LCMS (Sean Currin)

Session 12C: Ethics of HIV testing (Riana van Zyl)

Session 12C: Transitioning children and adolescents to adult services (Gillian Sorour)

Session 12C: Peer support models in adolescent HIV care (Jackie Hoare)

Session 13A: First-line (Nomathemba Chandiwana)

Session 13A: Second-line (Jeremy Nel)

Session 13B: An update on INSTI use in neonates – will there be a role in transmission prevention and treatment? (Adrie Bekker)

Session 13B: DTG and TB treatment in children – Pk data and clinical outcomes (Mo Archary)

Session 13B: Will tenofovir alafenamide-based ART for children & young adolescents find a plan in SA (Leon Levin)

Session 13C: The Aging Woman Living with HIV (Mary Adam)

Session 13C: Cervical Cancer and HPV (Motshedisi Sebitloane)

Session 13C: Mental health of Women living with HIV (Sibongile Mashapu)

Session 14: Long acting injectables debate (Roy Gulick)

Session 14: Long acting injectables debate (Gary Maartens)

Friday, 10 November 2023

Session 16A: Introduction to HIV cure (Monique Nijhuis)

Session 16A: Characterisation of the (intact) viral reservoir at initiation and at 96 weeks of ART in PLWH in South Africa (Lucas Hermans)

Session 16A: Immunological approaches towards HIV cure (Thumbi Ndung’u)

Session 16B: Renal impairment (Jeremy Nel)

Session 16B: Neuro (Cerebral space occupying lesions, acute and sub-acute/chronic meningitis, altered mental state) (Tom Boyles)

Session 16B: Respiratory presentation (Gary Maartens)

Session 16B: An approach to a patient with AHD that is deteriorating despite treatment for an OI (Tom Boyles)

Session 16C: Drug interactions with TLD (Christi Jackson)

Session 16C: DTG and weight gain (Simiso Sokhela)

Session 16C: TLD and renal dysfunction – when to switch ARVs and how to dose for renal impairment. (Phetho Mangena)

Session 18A: Moral harm or moral injury (Heidi Matisonn)

Session 18A: Consent options for biobanking (Lyn Horn)

Session 18B: Updated TB treatment guidelines for children – How it affects children living with HIV (James Nuttall)

Session 18C: Clinical skills building – Case discussion (Yunus Moosa)

Session 19A: Longer term virologic outcomes with TLD in second-line (Ying Zhao)

Session 19A: Identifying nonadherence and improving linkage to support: Interim progress from the SUSTAIN Study (Lauren Jennings)

Session 19A: Causes of death in PLWH in the post – 95-95-95 era: Lessons from five AHF clinics in Eswatini (Yves Mafulu)

Session 19A: Retrospective file audit among PrEP users attending public healthcare facilities who acquired HIV: Findings from two provinces in SA (Zamazamela Shelembe)

Session 19A: Understanding geospatial distribution of new HIV infections using HIV regency testing data for informed HIV response strategies: Lessons from Mberengwa district of Zimbabwe, 2023 (Obet Sibanda)

Session 19A: Integration of PrEP for pregnancy and postpartum women in antenatal and postnatal care in SA: Results from an implementation science study (Aurelie Nelson)

Session 19A: Fidelity in the implementation of urine LF-LAM testing guidelines in three community health centres in in Bojanala District, South Africa (Mamothe Makgabo)

Session 19B: Hepatitis B in the Southern African context (Jantjie Taljaard)

Session 19B: Congenital syphilis (Tendesayi Kufa-Chakezha)

Session 19C: Overview of PAVE (Mark Cotton)

Session 19C: Working with the community for complex HIV remission studies (Sharon Kruger)

Session 20: New and investigational ART agents (Roy Gulick)

Session 20: The future role of long acting agents in Africa (Sinead Delany-Moretlwe)

POSTER ABSTRACT PRESENTATIONS:

Early Identification of ART missed doses: baseline data from the RETAIN study (Lauren Jennings)

Risk factors for early nonadherence identification and successful linkage (Lauren Jennings)

Tenofovir induced hypophosphataemic osteomalacia (Maryke de Villiers)

WhatsApp-based microlearning for HIV training of healthcare workers (Briony Chisholm)

HIV PrEP: the bi-directional implications of exclusion from blood donation (Kamela Mahlakwane)

“First do no harm”: A case series (Linda Mandikiyana Chirimuta)

Clinical, pharmacokinetic, and genetic determinants of early change in serum creatinine (Rephaim Mpofu)

Viral suppression in adults on Efavirenz and Dolutegravir (Christina Maluleke)

Cutaneous signs and symptoms of treatment failure (Lehlohonolo Makhakhe)

Prevalence of hypertension and associated factors among young adults (Linda Mandikiyana Chirimuta)

To save someone’s life… It’s something great” (Elizabeth Kelechi Oladimeji)

13 –cycle dispensing as a theoretical systems solution to minimising festive season disruption (Philiswa Mnyaka)

Outcomes of multi-month dispensing of antiretroviral therapy (Varaidzo Kachingwe)

A Social Impact Bond to improve HIV and pregnancy outcomes (Lee-Ann Davids)

The South African community pharmacy sector (Tsitsi Nyamuzihwa)

Opt out Blood Borne Virus (BBV) testing in Emergency Departments (EDs) (Ian Cormack)

A decade of HIV self-testing: Practical lessons learnt (Mohammed Majam)

A camera that saves lives (Radhika Krishnan)

Secondary syphilis presenting with alopecia and leukoderma (Sukoluhle Khumalo)

A dual infection by cytomegalovirus and varicella zoster virus of the central nervous system (Thandekile Manzini)

The implementation of the updated paediatric HIV guidelines (Michael Christie)

Impact of COVID-19 pandemic on sexual activity (Sinead Delany-Moretlwe)

Closing the gap in pediatric treatment (Mulundu Mumbalanga)

Exploring the guidance and attitudes of healthcare workers (Erin von der Heyden)

Missed Diagnostic Opportunities within the HIV Early Infant Diagnosis programme (Cherise Naicker)

Contraception use among male commuters in Gauteng Province (Nkoleleng Mashilo)

HIV testing and Case detection dynamics (Bandile Ndlazi)

ARV prophylaxis beyond the perinatal period in high-risk breastfeeding infants (Linda Mandikiyana Chirimuta)

Utilization of an e-platform for oral PrEP initiation and continuation (Tsitsi Nyamuzihwa)

Assessing knowledge of attitude to and stigma towards PrEP (Boitshoko Moche)

Disseminated TB in people living with HIV (Marcia Vermeulen)

A review of all suspected drug-induced-liver-injury (DILI) cases (Anri Uys)

Implementing Antiretroviral Treatment Programmes to support employees (Tselane Mapana)

The use of urine lipoarabinomannan (LAM) test in clinical decision-making regarding empiric tuberculosis (TB) treatment (Maryke de Villiers)

Weight estimation amongst adults hospitalised with possible HIV-associated disseminated TB (Liberty Cele)

Opting Out of PrEP Among MSM And Transgender People in Ekurhuleni, South Africa (Matshidiso Chabane)

Home deliveries of HIV prevention and treatment drugs support accessibility to and uptake of HIV services (Matshidiso Chabane)

—————————————————————————————————————————————————————

Southern African HIV Clinicians Society Conference 2021 – Presentations:

Wednesday, 20 October 2021

Workshop B: Understanding patients reinitiating antiretroviral therapy in two South African districts | Kate Rees

Workshop G: Minimum package of clinical care | Zamasomi Luvuno and Elma de Vries

Thursday, 21 October 2021

Session 1: Undetectable Equals Untransmittable Campaign Is a solution to End HIV/Aids by 2030 | Mandisa Dukashe

Session 2B: Paediatric ART optimization and simplification in the current South African context | James Nuttall

Session 5: The D2EFT Trial: Towards simplified second line antiretroviral therapy | Richard Kaplan

Friday, 22 October 2021

Session 9: Viral load management | Annemarie Wensing

Session 11: HIV & cancer | Prinitha Pillay

Saturday, 23 October 2021

Session 12B: Digitization of adult guidelines | Jeremy Nel

Session 12B: Harm reduction guidelines | Andrew Scheibe

Session 12B: Guidelines for solid organ transplantation | Jeremy Nel

Session 12C: Hepatitis and climate change | Ahmed Cordie

Session 13: Pulmonary infections in advanced HIV disease | Gary Maartens

Session 13: Advanced HIV Disease – Approach to Diarrhoea in HIV | Dave Stead

Session 13: Advanced HIV Disease in primary care | Ian Proudfoot

—————————————————————————————————————————————————————

Southern African HIV Clinicians Society Conference 2018 – Presentations:

Pre-conference workshop A

Basics to understand HIV drug resistance | Carole Wallis
How do we measure HIV drug resistance | Monique Nijhuis
Impact of ART resistance in sub Saharan Africa | Elliot Raizes
Barriers to adherence: predictors and markers of treatment response | John de Wit
Understanding virological failure | Annemarie Wensing
Integrated adherence counselling using biomedical and socio-economic information | Lucas Hermans
Therapy success and failure: first, second and third line therapy | Francois Venter
DTG Global roll out | Ava Avalos
Future trends of drug resistance and prospects of antiviral therapy | Douglas Richman

Pre-conference workshop B

How to administer PrEP: a typical clinical consultation | Muhangwi Mulaudzi

Session 1A

Previously on PrEP, now pregnant. What to do? | Tshidi Sebitloane
Teen adherence | Juliet Houghton
Breast abnormalities in adolescents receiving ART | Jackie Dunlop

Session 1B

Case presentation: Treatment experienced and PrEP | Eric Hefer
Case presentation: Pirates of the abdomen | Kim Pieton
Case presentation: A palatal mass and a head-scratcher | Michelle Venter

Session 1C

Cases – primary healthcare, rural doctors | Ndiviwe Mphothulo, Jenny Nash
Managing HIV and the role of the primary healthcare team | Jenny Nash
Missed Clinical Management Opportunities | Gloria Mthombeni
Nurse cases | Talitha Crowley

Session 3

Opening | Desmond Martin
HIV replication: principles and prevention | Douglas Richman

Session 4A

Session 5

How are we doing with Universal Test and Treat? | Francois Venter
How are we doing with viral suppression? | Sergio Carmona
Pretreatment drug resistance and new treatment paradigms in first-line ART | Michelle Moorhouse

Session 6A

Pharmacovigilance | Karen Cohen
Pregnancy register | Mukesh Dheda
Registers and centralised reporting | Ruth Lancaster

Session 6B

Swallowing tablets | Melanie Collins
Optimising formulations | Carol Ruffell
The latest on infant testing, and how to access | Gayle Sherman
Treating children | Helena Rabie

Session 6C

Whistle-blowing in the health-sector | Marije Versteeg-Mojanaga
Ethics on how health budgets are split | Marije Versteeg-Mojanaga

Session 8A

Kaposi Sarcoma and Lymphoma | Zainab Mohamed

Session 8B

Viral resistance first-line and second-line | Graeme Meintjes
Third-line treatment. Feedback on outcome of patients on national third-line regimen | Michelle Moorhouse

Session 8C

Non-biomedical approaches | Sue Goldstein
Condoms | Mags Beksinska
Update on trials of vaccines and monoclonals in SA; how PrEP could augment these approaches | Fatima Laher
Voluntary medical male circumcision | Limakatso Lebina
Treatment as prevention | Francois Venter

Session 9A

NRTIs (Yunus Moosa)
NNRTIs (Michelle Moorhouse)
Drug-drug interaction (Gary Maartens)

Session 9C

What are the numbers telling us | Andrew Boulle
How the epidemic informs resource planning | Zukiswa Pinini
Cost effectiveness of TLD versus TEE | Gesine Meyer-Rath

Session 10A

HIVDB genotypic drug resistance interpretation program | Robert Shafer

Session 10B

Integrating HIV prevention with other services | Natasha Davies
How to tell a teenager they have HIV: A practical approach | Julia Turner
Uptake and yield of a 24/7 HIV testing service across four Eastern Cape hospital Emergency departments | Dave Stead

Session 11

Implications of scarcer resources for 90:90:90 | Gloria Maimela

Session 12

Why do we need cure | John Mellors
How do you measure cure | Monique Nijhuis

Session 13A

An approach to intracranial mass lesions in HIV patients | Dave Stead
Endemic mycoses in HIV patients | Jade Mogambery
An approach to chronic diarrhoea | Sipho Dlamini

Session 13B

TB in adults and HIV-TB co-infection | Ndiviwe Mphothulo
TB and HIV co-infection including IRIS | Richard Lessells

Session 13C

Injecting drug users in the region | Andrew Scheibe
Engaging with sex workers | Naomi Hill
Testing in taxi ranks | Thandeka Khoza

Session 15

Could good point-of-care testing revolutionise issues in the region? | Tim Tucker

Session 16A

Case presentation | Farai Russell Sigauke
Clinical skill building | Richard Lessells

Session 16B

Should the private sector be treating TB? Yes | Moeketsi Mathe

Session 16C

Where are we with PMTCT, including epidemiology | Landon Myer
Transmission of HIV in breastfeeding | Ameena Goga
Pregnant women on ART – programmatic issues | Coceka Mnyani

Session 17

Dolutegravir in pregnancy – overview | Landon Myer
DolPHIN-1 | Catherine Orrell
Dolutegravir rollout | Steven Smith

Session 19

Vaccinations – overview | Benjamin Kagina
Influenza vaccines | Marta Nunes
SAHCS vaccination guidelines | Sipho Dlamini

Session 20A

Inflammation | Dave Spencer
Hypertension | Ebrahim Variava
Obesity | Denasha Reddy
Mental health | John Joska
Injection drug use, HIV and hepatitis | Moeketsi Mathe

Session 20B

Ethico-legal framework for biobank research in SA | Safia Mahomed
EMGuidance | Mohammed Dalwai

Session 20C

Strategies to achieve STI control in South Africa | Remco Peters
Hepatitis C | Andrew Scheibe

Session 22A

Care of aging patients | Marlin McKay
Palliative care | Dave Spencer

Session 22B

New ARVs and surveillance | Michelle Moorhouse
Low-dose darunavir | Francois Venter

Session 22C

Constructing TB cascades to inform TB programme improvement | Kate Rees)
Continued Use of PrEP among Sex Workers in Six Sites in South Africa | Cara O’Connor
Linking paediatric, adolescent and adult patients to care through the implementation of clinic navigators in high volume facilities | Chantal Smith
Perceptions of HIV-Self Screening | Nthabiseng Koloane
Viral load suppression among pregnant women presenting on ART in antenatal care; Chiredzi District Zimbabwe | Talent Maphosa
Triple-NRTI regimens while on TB treatment in a resource constrained setting – a paediatric cohort analysis | Jennifer Minnaar
Youth Care Clubs: Optimising clinic time, fostering peer support, improving adherence | Moira Beery

Session 23A

Vaccination guidelines | Sipho Dlamini
Safer conception guidelines | Natasha Davies
Adult antiretroviral therapy guidelines | Michelle Moorhouse
Palliative care guidelines | Dave Spencer

Session 23B

What is new in adherence | Catherine Orrell
Virological monitoring – how it relates to adherence | Richard Lessells
Self screening | Naleni Rhagnath

Session 23C

Quality Improvement | Lauren de Kock

Session 24

Big challenges in TB drug resistance | Richard Lessells
Big challenges in introducing and scaling up new prevention technologies | Helen Rees
Big challenges in public health with essential medicine availability